 James Burton
Concepts (377)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Transplantation | 31 | 2023 | 946 | 3.540 |
Why?
| | Hepatitis C | 17 | 2021 | 239 | 2.670 |
Why?
| | Antiviral Agents | 17 | 2021 | 673 | 2.250 |
Why?
| | Hepatitis C, Chronic | 11 | 2021 | 149 | 2.200 |
Why?
| | Ribavirin | 8 | 2015 | 87 | 1.500 |
Why?
| | Hepacivirus | 11 | 2021 | 240 | 0.920 |
Why?
| | Proline | 6 | 2015 | 71 | 0.910 |
Why?
| | Protease Inhibitors | 3 | 2018 | 107 | 0.900 |
Why?
| | Kidney Transplantation | 4 | 2023 | 593 | 0.820 |
Why?
| | Liver Function Tests | 3 | 2022 | 111 | 0.800 |
Why?
| | Liver | 10 | 2023 | 1872 | 0.740 |
Why?
| | Oligopeptides | 5 | 2015 | 256 | 0.720 |
Why?
| | Interferon-alpha | 3 | 2014 | 193 | 0.720 |
Why?
| | Drug Therapy, Combination | 12 | 2018 | 1006 | 0.690 |
Why?
| | Patient Selection | 3 | 2020 | 725 | 0.640 |
Why?
| | Polyethylene Glycols | 4 | 2014 | 577 | 0.640 |
Why?
| | Interferons | 4 | 2015 | 157 | 0.620 |
Why?
| | Graft Rejection | 4 | 2018 | 555 | 0.570 |
Why?
| | Living Donors | 7 | 2022 | 331 | 0.560 |
Why?
| | Recurrence | 12 | 2015 | 1011 | 0.510 |
Why?
| | Liver Failure | 3 | 2016 | 93 | 0.480 |
Why?
| | Postoperative Complications | 5 | 2022 | 2325 | 0.480 |
Why?
| | Non-alcoholic Fatty Liver Disease | 3 | 2022 | 286 | 0.400 |
Why?
| | Immunocompromised Host | 1 | 2013 | 207 | 0.370 |
Why?
| | Viral Nonstructural Proteins | 2 | 2014 | 60 | 0.350 |
Why?
| | Graft Survival | 4 | 2023 | 510 | 0.340 |
Why?
| | Humans | 74 | 2023 | 125131 | 0.330 |
Why?
| | Tissue Donors | 4 | 2021 | 352 | 0.330 |
Why?
| | Home Care Services, Hospital-Based | 2 | 1999 | 11 | 0.320 |
Why?
| | Middle Aged | 35 | 2022 | 29112 | 0.320 |
Why?
| | T-Lymphocytes, Regulatory | 2 | 2008 | 364 | 0.310 |
Why?
| | Decision Support Techniques | 2 | 2018 | 395 | 0.300 |
Why?
| | Esophageal and Gastric Varices | 1 | 2007 | 39 | 0.280 |
Why?
| | Simeprevir | 2 | 2018 | 9 | 0.280 |
Why?
| | Acute Disease | 7 | 2008 | 1016 | 0.280 |
Why?
| | Tissue and Organ Procurement | 2 | 2023 | 258 | 0.270 |
Why?
| | Severity of Illness Index | 5 | 2021 | 2848 | 0.260 |
Why?
| | Health Services for the Aged | 5 | 2000 | 78 | 0.260 |
Why?
| | Liver Cirrhosis | 3 | 2015 | 249 | 0.250 |
Why?
| | CD4-Positive T-Lymphocytes | 2 | 2008 | 997 | 0.250 |
Why?
| | Reproducibility of Results | 5 | 2022 | 3047 | 0.250 |
Why?
| | Geriatrics | 7 | 2000 | 73 | 0.240 |
Why?
| | Cholates | 2 | 2022 | 2 | 0.240 |
Why?
| | Health Care Rationing | 1 | 2004 | 51 | 0.240 |
Why?
| | United States | 17 | 2023 | 13613 | 0.230 |
Why?
| | Male | 41 | 2021 | 60792 | 0.230 |
Why?
| | Home Care Services | 3 | 1997 | 246 | 0.230 |
Why?
| | Solitary Kidney | 1 | 2023 | 9 | 0.230 |
Why?
| | Viremia | 3 | 2021 | 131 | 0.230 |
Why?
| | Cecal Neoplasms | 1 | 2003 | 1 | 0.220 |
Why?
| | Jejunoileal Bypass | 1 | 2003 | 1 | 0.220 |
Why?
| | Aged | 29 | 2018 | 20859 | 0.220 |
Why?
| | Treatment Outcome | 15 | 2022 | 9790 | 0.220 |
Why?
| | Reoperation | 4 | 2007 | 571 | 0.210 |
Why?
| | Liver Diseases | 1 | 2006 | 325 | 0.210 |
Why?
| | Female | 39 | 2021 | 64889 | 0.210 |
Why?
| | Cholangitis | 1 | 2022 | 26 | 0.200 |
Why?
| | Transplant Recipients | 2 | 2021 | 150 | 0.200 |
Why?
| | Recombinant Proteins | 4 | 2014 | 1327 | 0.190 |
Why?
| | Forecasting | 3 | 2014 | 379 | 0.190 |
Why?
| | Cholangitis, Sclerosing | 1 | 2022 | 76 | 0.190 |
Why?
| | Liver Circulation | 1 | 2021 | 22 | 0.190 |
Why?
| | Colonoscopy | 1 | 2003 | 212 | 0.180 |
Why?
| | Nursing Homes | 2 | 1994 | 150 | 0.180 |
Why?
| | Famous Persons | 1 | 2000 | 6 | 0.180 |
Why?
| | Carbon Isotopes | 1 | 2021 | 125 | 0.180 |
Why?
| | Adult | 21 | 2021 | 33167 | 0.180 |
Why?
| | Deuterium | 1 | 2021 | 80 | 0.180 |
Why?
| | Consensus Development Conferences as Topic | 1 | 2020 | 33 | 0.180 |
Why?
| | Healthy Volunteers | 1 | 2021 | 214 | 0.170 |
Why?
| | Sofosbuvir | 2 | 2021 | 53 | 0.170 |
Why?
| | Donor Selection | 1 | 2020 | 74 | 0.170 |
Why?
| | Carbamates | 2 | 2021 | 38 | 0.170 |
Why?
| | Blood Coagulation Disorders | 1 | 2022 | 220 | 0.160 |
Why?
| | Allografts | 1 | 2020 | 137 | 0.160 |
Why?
| | Kidney | 3 | 2023 | 1379 | 0.160 |
Why?
| | Reference Values | 1 | 2021 | 818 | 0.160 |
Why?
| | Antibiotic Prophylaxis | 1 | 2020 | 101 | 0.160 |
Why?
| | Practice Patterns, Physicians' | 2 | 2005 | 1280 | 0.150 |
Why?
| | Hepatitis, Autoimmune | 1 | 2018 | 34 | 0.150 |
Why?
| | Cohort Studies | 6 | 2018 | 5348 | 0.150 |
Why?
| | Biopsy | 2 | 2020 | 1093 | 0.150 |
Why?
| | Coronary Artery Disease | 2 | 2020 | 721 | 0.150 |
Why?
| | Geriatric Assessment | 2 | 1997 | 188 | 0.150 |
Why?
| | RNA, Viral | 4 | 2015 | 587 | 0.150 |
Why?
| | Physician-Patient Relations | 3 | 2000 | 517 | 0.150 |
Why?
| | Heterocyclic Compounds, 3-Ring | 1 | 2018 | 29 | 0.150 |
Why?
| | Eligibility Determination | 2 | 1997 | 68 | 0.150 |
Why?
| | Thrombolytic Therapy | 2 | 1997 | 120 | 0.150 |
Why?
| | Leukocyte Count | 1 | 2018 | 315 | 0.150 |
Why?
| | Consensus | 1 | 2020 | 577 | 0.150 |
Why?
| | Coronary Angiography | 3 | 2020 | 353 | 0.150 |
Why?
| | Drug Interactions | 3 | 2013 | 368 | 0.140 |
Why?
| | Diagnostic Tests, Routine | 1 | 2018 | 96 | 0.140 |
Why?
| | Forkhead Transcription Factors | 2 | 2008 | 186 | 0.140 |
Why?
| | HIV Integrase Inhibitors | 1 | 2018 | 63 | 0.140 |
Why?
| | Retrospective Studies | 11 | 2022 | 13708 | 0.140 |
Why?
| | Family Planning Policy | 1 | 2016 | 1 | 0.140 |
Why?
| | End Stage Liver Disease | 1 | 2018 | 83 | 0.140 |
Why?
| | Adenocarcinoma | 1 | 2003 | 840 | 0.140 |
Why?
| | Odds Ratio | 4 | 2015 | 1050 | 0.130 |
Why?
| | Health Planning | 1 | 2016 | 50 | 0.130 |
Why?
| | Public Policy | 1 | 2016 | 71 | 0.130 |
Why?
| | Long-Term Care | 1 | 2016 | 78 | 0.130 |
Why?
| | Prognosis | 5 | 2020 | 3616 | 0.130 |
Why?
| | Fibrosis | 1 | 2018 | 497 | 0.130 |
Why?
| | Population Dynamics | 1 | 2016 | 143 | 0.130 |
Why?
| | Aortic Valve Insufficiency | 1 | 2015 | 47 | 0.130 |
Why?
| | Prospective Studies | 7 | 2021 | 6818 | 0.130 |
Why?
| | Macrocyclic Compounds | 1 | 2014 | 9 | 0.120 |
Why?
| | Young Adult | 7 | 2021 | 11384 | 0.120 |
Why?
| | Time Factors | 10 | 2018 | 6780 | 0.120 |
Why?
| | Program Evaluation | 1 | 1999 | 896 | 0.120 |
Why?
| | Developing Countries | 1 | 2016 | 269 | 0.120 |
Why?
| | Genotype | 3 | 2015 | 1960 | 0.120 |
Why?
| | Homes for the Aged | 1 | 1994 | 21 | 0.120 |
Why?
| | Anilides | 1 | 2014 | 70 | 0.120 |
Why?
| | Comprehensive Health Care | 1 | 1994 | 23 | 0.120 |
Why?
| | Survival Analysis | 4 | 2018 | 1341 | 0.120 |
Why?
| | Patient Satisfaction | 1 | 1998 | 643 | 0.110 |
Why?
| | Glucocorticoids | 1 | 2018 | 554 | 0.110 |
Why?
| | Factor Xa Inhibitors | 2 | 2005 | 142 | 0.110 |
Why?
| | Transcatheter Aortic Valve Replacement | 1 | 2015 | 164 | 0.110 |
Why?
| | Serine Proteinase Inhibitors | 1 | 2013 | 38 | 0.110 |
Why?
| | Transplantation | 1 | 2013 | 26 | 0.110 |
Why?
| | Follow-Up Studies | 6 | 2016 | 4824 | 0.110 |
Why?
| | Pyridazines | 1 | 2013 | 59 | 0.100 |
Why?
| | Spinal Diseases | 1 | 1993 | 47 | 0.100 |
Why?
| | Quality of Life | 4 | 2018 | 2580 | 0.100 |
Why?
| | DEAD-box RNA Helicases | 1 | 2013 | 59 | 0.100 |
Why?
| | Multivariate Analysis | 3 | 2015 | 1561 | 0.100 |
Why?
| | Mental Health | 1 | 2018 | 594 | 0.100 |
Why?
| | Cholangiocarcinoma | 1 | 2012 | 34 | 0.100 |
Why?
| | Myocardial Infarction | 3 | 2005 | 1142 | 0.100 |
Why?
| | Bile Ducts, Intrahepatic | 1 | 2012 | 50 | 0.100 |
Why?
| | Immunosuppressive Agents | 2 | 2013 | 693 | 0.100 |
Why?
| | Bile Duct Neoplasms | 1 | 2012 | 52 | 0.100 |
Why?
| | Aortic Valve Stenosis | 1 | 2015 | 332 | 0.100 |
Why?
| | Postoperative Care | 1 | 2013 | 245 | 0.090 |
Why?
| | Hepatic Insufficiency | 1 | 2010 | 4 | 0.090 |
Why?
| | Interleukins | 1 | 2013 | 243 | 0.090 |
Why?
| | Chemoradiotherapy | 1 | 2012 | 199 | 0.090 |
Why?
| | Th1 Cells | 2 | 2008 | 137 | 0.090 |
Why?
| | Preoperative Care | 1 | 2013 | 343 | 0.090 |
Why?
| | Blood Component Transfusion | 1 | 2011 | 84 | 0.090 |
Why?
| | Death Certificates | 1 | 1990 | 27 | 0.090 |
Why?
| | Autopsy | 1 | 1990 | 93 | 0.090 |
Why?
| | Aged, 80 and over | 9 | 2015 | 6936 | 0.080 |
Why?
| | Nucleosides | 1 | 2009 | 26 | 0.080 |
Why?
| | Longitudinal Studies | 4 | 2016 | 2669 | 0.080 |
Why?
| | Primary Health Care | 2 | 1993 | 1660 | 0.080 |
Why?
| | Myocardial Stunning | 1 | 2009 | 5 | 0.080 |
Why?
| | Uremia | 1 | 2009 | 18 | 0.080 |
Why?
| | Prodrugs | 1 | 2009 | 44 | 0.080 |
Why?
| | Erythrocyte Transfusion | 1 | 2011 | 207 | 0.080 |
Why?
| | Drug Resistance, Viral | 1 | 2009 | 100 | 0.080 |
Why?
| | RNA | 1 | 2015 | 875 | 0.080 |
Why?
| | Cross Infection | 1 | 2011 | 220 | 0.080 |
Why?
| | MicroRNAs | 1 | 2015 | 660 | 0.080 |
Why?
| | Vitamin B 12 Deficiency | 1 | 1988 | 75 | 0.080 |
Why?
| | Drug Discovery | 1 | 2009 | 129 | 0.080 |
Why?
| | Urinary Incontinence | 1 | 1988 | 60 | 0.080 |
Why?
| | Risk Factors | 8 | 2020 | 9549 | 0.080 |
Why?
| | Biomarkers | 2 | 2015 | 3736 | 0.070 |
Why?
| | Thrombelastography | 2 | 2022 | 199 | 0.070 |
Why?
| | Interferon-gamma | 2 | 2008 | 749 | 0.070 |
Why?
| | Predictive Value of Tests | 3 | 2020 | 1992 | 0.070 |
Why?
| | Propionates | 2 | 2005 | 36 | 0.070 |
Why?
| | Registries | 1 | 2016 | 2050 | 0.070 |
Why?
| | Platelet Count | 1 | 2007 | 89 | 0.070 |
Why?
| | Patient Readmission | 2 | 2010 | 694 | 0.070 |
Why?
| | Acute Lung Injury | 1 | 2011 | 319 | 0.070 |
Why?
| | Naphthalenes | 2 | 2005 | 50 | 0.070 |
Why?
| | Likelihood Functions | 1 | 2007 | 141 | 0.070 |
Why?
| | Ventricular Function, Left | 2 | 2009 | 511 | 0.070 |
Why?
| | Interleukin-7 Receptor alpha Subunit | 1 | 2006 | 11 | 0.070 |
Why?
| | Receptors, Interleukin-7 | 1 | 2006 | 26 | 0.070 |
Why?
| | Viral Load | 2 | 2021 | 426 | 0.070 |
Why?
| | Models, Statistical | 2 | 2015 | 664 | 0.070 |
Why?
| | Behavior Therapy | 1 | 1988 | 254 | 0.070 |
Why?
| | ROC Curve | 1 | 2007 | 501 | 0.060 |
Why?
| | Logistic Models | 3 | 2015 | 2040 | 0.060 |
Why?
| | Renal Dialysis | 1 | 2009 | 393 | 0.060 |
Why?
| | Heparin | 4 | 2005 | 236 | 0.060 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2013 | 2135 | 0.060 |
Why?
| | Proportional Hazards Models | 2 | 2020 | 1191 | 0.060 |
Why?
| | Clinical Trials as Topic | 1 | 2009 | 1006 | 0.060 |
Why?
| | Serine Endopeptidases | 1 | 2005 | 104 | 0.060 |
Why?
| | Ambulatory Care | 1 | 1988 | 511 | 0.060 |
Why?
| | Chi-Square Distribution | 2 | 2011 | 558 | 0.060 |
Why?
| | Treatment Failure | 1 | 2005 | 348 | 0.060 |
Why?
| | Skilled Nursing Facilities | 1 | 1985 | 133 | 0.060 |
Why?
| | Incidence | 2 | 2010 | 2578 | 0.060 |
Why?
| | Hepatitis B Antibodies | 1 | 2003 | 10 | 0.060 |
Why?
| | Reperfusion Injury | 1 | 2006 | 284 | 0.060 |
Why?
| | Hepatitis B virus | 1 | 2003 | 25 | 0.060 |
Why?
| | Endoscopes, Gastrointestinal | 1 | 2003 | 12 | 0.060 |
Why?
| | Kidney Failure, Chronic | 1 | 2009 | 523 | 0.060 |
Why?
| | House Calls | 1 | 1985 | 138 | 0.060 |
Why?
| | Health Care Surveys | 1 | 2005 | 574 | 0.050 |
Why?
| | Length of Stay | 3 | 2011 | 1077 | 0.050 |
Why?
| | Continuity of Patient Care | 1 | 1985 | 281 | 0.050 |
Why?
| | Pilot Projects | 3 | 2009 | 1530 | 0.050 |
Why?
| | Aging | 1 | 1993 | 1706 | 0.050 |
Why?
| | Colectomy | 1 | 2003 | 88 | 0.050 |
Why?
| | Risk Assessment | 4 | 2015 | 3274 | 0.050 |
Why?
| | Sensitivity and Specificity | 1 | 2007 | 1885 | 0.050 |
Why?
| | Choledochostomy | 1 | 2022 | 15 | 0.050 |
Why?
| | Anastomosis, Roux-en-Y | 1 | 2022 | 35 | 0.050 |
Why?
| | Clinical Protocols | 1 | 2003 | 258 | 0.050 |
Why?
| | Plasma | 2 | 2014 | 224 | 0.050 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2006 | 717 | 0.050 |
Why?
| | DNA, Viral | 1 | 2003 | 360 | 0.050 |
Why?
| | Proof of Concept Study | 1 | 2021 | 48 | 0.050 |
Why?
| | Critical Care | 1 | 1985 | 563 | 0.050 |
Why?
| | Heterocyclic Compounds, 4 or More Rings | 1 | 2021 | 16 | 0.050 |
Why?
| | Sustained Virologic Response | 1 | 2021 | 33 | 0.050 |
Why?
| | Referral and Consultation | 1 | 1985 | 705 | 0.050 |
Why?
| | Health Planning Councils | 1 | 2000 | 6 | 0.050 |
Why?
| | Government | 1 | 2000 | 12 | 0.040 |
Why?
| | Thrombosis | 1 | 2004 | 319 | 0.040 |
Why?
| | Mental Disorders | 1 | 1988 | 976 | 0.040 |
Why?
| | Feasibility Studies | 2 | 2004 | 806 | 0.040 |
Why?
| | Blood Coagulation | 1 | 2022 | 229 | 0.040 |
Why?
| | Cholangiopancreatography, Endoscopic Retrograde | 1 | 2022 | 184 | 0.040 |
Why?
| | Muscular Atrophy | 1 | 2000 | 86 | 0.040 |
Why?
| | Adolescent | 6 | 2015 | 19411 | 0.040 |
Why?
| | Baltimore | 1 | 1999 | 47 | 0.040 |
Why?
| | Anticoagulants | 1 | 2004 | 587 | 0.040 |
Why?
| | Specialization | 1 | 2000 | 133 | 0.040 |
Why?
| | Nephrectomy | 1 | 2020 | 163 | 0.040 |
Why?
| | History, 20th Century | 1 | 2000 | 290 | 0.040 |
Why?
| | Cardiac Surgical Procedures | 1 | 2004 | 490 | 0.040 |
Why?
| | Streptokinase | 2 | 1997 | 10 | 0.040 |
Why?
| | Drug Administration Schedule | 1 | 2021 | 760 | 0.040 |
Why?
| | Hospitals, University | 1 | 1999 | 193 | 0.040 |
Why?
| | Postoperative Period | 2 | 2016 | 317 | 0.040 |
Why?
| | General Surgery | 1 | 2000 | 152 | 0.040 |
Why?
| | Linear Models | 1 | 2021 | 870 | 0.040 |
Why?
| | Withholding Treatment | 1 | 2018 | 70 | 0.040 |
Why?
| | Oxazines | 1 | 2018 | 26 | 0.040 |
Why?
| | Diagnosis-Related Groups | 1 | 1997 | 34 | 0.040 |
Why?
| | Patient Admission | 1 | 1999 | 198 | 0.040 |
Why?
| | Safety | 1 | 1999 | 309 | 0.040 |
Why?
| | Osteoporosis | 1 | 2000 | 243 | 0.040 |
Why?
| | Area Under Curve | 1 | 2018 | 305 | 0.040 |
Why?
| | Pyridones | 1 | 2018 | 120 | 0.030 |
Why?
| | Cause of Death | 2 | 2007 | 394 | 0.030 |
Why?
| | Lymphocytes | 1 | 2018 | 356 | 0.030 |
Why?
| | Myocardial Reperfusion Injury | 1 | 1997 | 107 | 0.030 |
Why?
| | Attitude | 1 | 1998 | 248 | 0.030 |
Why?
| | Tissue Plasminogen Activator | 2 | 1997 | 245 | 0.030 |
Why?
| | Data Collection | 1 | 1999 | 682 | 0.030 |
Why?
| | Fatigue | 1 | 2018 | 324 | 0.030 |
Why?
| | China | 1 | 2016 | 225 | 0.030 |
Why?
| | Piperazines | 1 | 2018 | 331 | 0.030 |
Why?
| | Phlebotomy | 1 | 2015 | 13 | 0.030 |
Why?
| | 2-Naphthylamine | 1 | 2014 | 7 | 0.030 |
Why?
| | Family Characteristics | 1 | 2016 | 171 | 0.030 |
Why?
| | Population | 1 | 2015 | 32 | 0.030 |
Why?
| | Half-Life | 1 | 2015 | 150 | 0.030 |
Why?
| | Uracil | 1 | 2014 | 35 | 0.030 |
Why?
| | Cyclopropanes | 1 | 2014 | 81 | 0.030 |
Why?
| | Patient Reported Outcome Measures | 1 | 2017 | 270 | 0.030 |
Why?
| | North America | 1 | 2015 | 271 | 0.030 |
Why?
| | Cluster Analysis | 1 | 2016 | 497 | 0.030 |
Why?
| | Calcineurin Inhibitors | 1 | 2014 | 61 | 0.030 |
Why?
| | Social Class | 1 | 2016 | 232 | 0.030 |
Why?
| | Biological Assay | 1 | 2015 | 123 | 0.030 |
Why?
| | Lactams, Macrocyclic | 1 | 2014 | 47 | 0.030 |
Why?
| | Valine | 1 | 2014 | 78 | 0.030 |
Why?
| | Femoral Artery | 1 | 2015 | 182 | 0.030 |
Why?
| | Cadaver | 1 | 2015 | 338 | 0.030 |
Why?
| | Ritonavir | 1 | 2014 | 74 | 0.030 |
Why?
| | Sex Characteristics | 2 | 2015 | 699 | 0.030 |
Why?
| | Frail Elderly | 1 | 1994 | 112 | 0.030 |
Why?
| | Hepatocytes | 1 | 2014 | 207 | 0.030 |
Why?
| | DEAD Box Protein 58 | 1 | 2013 | 9 | 0.030 |
Why?
| | Leukocytes | 1 | 2014 | 292 | 0.030 |
Why?
| | Case-Control Studies | 2 | 2013 | 3326 | 0.030 |
Why?
| | Neutrophils | 1 | 2018 | 1250 | 0.030 |
Why?
| | Cholestasis | 1 | 2015 | 234 | 0.030 |
Why?
| | HIV-1 | 1 | 2018 | 787 | 0.030 |
Why?
| | Nitriles | 1 | 2013 | 159 | 0.030 |
Why?
| | Patient Acceptance of Health Care | 1 | 1998 | 716 | 0.030 |
Why?
| | Pain | 1 | 2018 | 767 | 0.020 |
Why?
| | Medicare Part B | 1 | 1991 | 8 | 0.020 |
Why?
| | Receptors, Immunologic | 1 | 2013 | 213 | 0.020 |
Why?
| | Prevalence | 1 | 2018 | 2488 | 0.020 |
Why?
| | Physical Examination | 1 | 1993 | 256 | 0.020 |
Why?
| | Emotions | 1 | 2016 | 525 | 0.020 |
Why?
| | Anxiety | 1 | 2018 | 924 | 0.020 |
Why?
| | Chromatography, Liquid | 1 | 2013 | 363 | 0.020 |
Why?
| | Sulfonamides | 1 | 2014 | 467 | 0.020 |
Why?
| | Alcoholism | 1 | 2018 | 819 | 0.020 |
Why?
| | Cross-Over Studies | 1 | 2013 | 485 | 0.020 |
Why?
| | Lumbar Vertebrae | 1 | 1993 | 218 | 0.020 |
Why?
| | Heart Transplantation | 1 | 1997 | 689 | 0.020 |
Why?
| | Attitude of Health Personnel | 1 | 1998 | 1048 | 0.020 |
Why?
| | Insurance, Health, Reimbursement | 1 | 1991 | 93 | 0.020 |
Why?
| | Health Services Needs and Demand | 1 | 1992 | 272 | 0.020 |
Why?
| | Phosphorylation | 1 | 2015 | 1694 | 0.020 |
Why?
| | Body Weight | 1 | 2015 | 959 | 0.020 |
Why?
| | Tandem Mass Spectrometry | 1 | 2013 | 431 | 0.020 |
Why?
| | Anti-Retroviral Agents | 1 | 2012 | 210 | 0.020 |
Why?
| | Research Design | 1 | 2016 | 1035 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2005 | 2026 | 0.020 |
Why?
| | Neoadjuvant Therapy | 1 | 2012 | 338 | 0.020 |
Why?
| | Erythrocytes | 1 | 2015 | 642 | 0.020 |
Why?
| | Pyrimidines | 1 | 2013 | 391 | 0.020 |
Why?
| | Depression | 1 | 2018 | 1236 | 0.020 |
Why?
| | Anemia, Pernicious | 1 | 1988 | 9 | 0.020 |
Why?
| | Obesity | 1 | 2022 | 2805 | 0.020 |
Why?
| | Urinary Incontinence, Stress | 1 | 1988 | 14 | 0.020 |
Why?
| | Diagnosis, Differential | 1 | 1993 | 1431 | 0.020 |
Why?
| | Biofeedback, Psychology | 1 | 1988 | 25 | 0.020 |
Why?
| | Fibrinogens, Abnormal | 1 | 2008 | 4 | 0.020 |
Why?
| | Gene Expression Profiling | 1 | 2015 | 1642 | 0.020 |
Why?
| | CD24 Antigen | 1 | 2008 | 19 | 0.020 |
Why?
| | Vitamin B 12 | 1 | 1988 | 116 | 0.020 |
Why?
| | Academic Medical Centers | 1 | 2010 | 447 | 0.020 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 1 | 2008 | 70 | 0.020 |
Why?
| | Myocardial Contraction | 1 | 2009 | 339 | 0.020 |
Why?
| | Genes, MHC Class II | 1 | 2007 | 73 | 0.020 |
Why?
| | Societies, Medical | 1 | 1991 | 754 | 0.020 |
Why?
| | Child | 2 | 2021 | 20014 | 0.020 |
Why?
| | Hospitalization | 1 | 1996 | 1960 | 0.020 |
Why?
| | Nurse Practitioners | 1 | 1988 | 116 | 0.020 |
Why?
| | Cytomegalovirus | 1 | 2007 | 153 | 0.020 |
Why?
| | Hospital Mortality | 1 | 2011 | 897 | 0.020 |
Why?
| | Stroke Volume | 1 | 2009 | 570 | 0.020 |
Why?
| | Organizational Affiliation | 1 | 1985 | 8 | 0.020 |
Why?
| | Internal Medicine | 1 | 1988 | 234 | 0.020 |
Why?
| | Immunity, Cellular | 1 | 2008 | 277 | 0.020 |
Why?
| | Dementia | 1 | 1988 | 218 | 0.020 |
Why?
| | Waiting Lists | 1 | 2007 | 231 | 0.020 |
Why?
| | Pressure Ulcer | 1 | 1985 | 33 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2016 | 4854 | 0.020 |
Why?
| | Injections, Intravenous | 1 | 1985 | 219 | 0.020 |
Why?
| | Partial Thromboplastin Time | 1 | 2005 | 52 | 0.020 |
Why?
| | Ultrasonography | 1 | 2009 | 757 | 0.010 |
Why?
| | Epitopes | 1 | 2006 | 450 | 0.010 |
Why?
| | Alleles | 1 | 2007 | 865 | 0.010 |
Why?
| | Immunologic Memory | 1 | 2006 | 322 | 0.010 |
Why?
| | Fluid Therapy | 1 | 1985 | 155 | 0.010 |
Why?
| | Pneumonia | 1 | 1990 | 610 | 0.010 |
Why?
| | International Normalized Ratio | 1 | 2004 | 46 | 0.010 |
Why?
| | Intraoperative Care | 1 | 2004 | 39 | 0.010 |
Why?
| | Blood Coagulation Tests | 1 | 2004 | 59 | 0.010 |
Why?
| | Genetic Predisposition to Disease | 1 | 2013 | 2382 | 0.010 |
Why?
| | Canada | 2 | 1997 | 359 | 0.010 |
Why?
| | HIV Infections | 1 | 2018 | 2588 | 0.010 |
Why?
| | Physician's Role | 1 | 1985 | 211 | 0.010 |
Why?
| | Flow Cytometry | 1 | 2006 | 1108 | 0.010 |
Why?
| | Drug Monitoring | 1 | 2004 | 186 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2014 | 5061 | 0.010 |
Why?
| | Blood Pressure | 1 | 2009 | 1735 | 0.010 |
Why?
| | Ischemia | 1 | 2005 | 383 | 0.010 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2007 | 1324 | 0.010 |
Why?
| | Electrocardiography | 1 | 2005 | 637 | 0.010 |
Why?
| | Colorado | 1 | 2011 | 4471 | 0.010 |
Why?
| | Hemorrhage | 1 | 2005 | 673 | 0.010 |
Why?
| | Foundations | 1 | 2000 | 21 | 0.010 |
Why?
| | Organizational Objectives | 1 | 2000 | 69 | 0.010 |
Why?
| | Patient Education as Topic | 1 | 1985 | 734 | 0.010 |
Why?
| | Models, Biological | 1 | 2007 | 1753 | 0.010 |
Why?
| | Phenotype | 1 | 2006 | 3153 | 0.010 |
Why?
| | Education, Medical | 1 | 2000 | 255 | 0.010 |
Why?
| | Vascular Patency | 1 | 1997 | 100 | 0.010 |
Why?
| | Coronary Circulation | 1 | 1997 | 140 | 0.010 |
Why?
| | Child, Preschool | 1 | 2009 | 9938 | 0.010 |
Why?
| | Interviews as Topic | 1 | 1997 | 649 | 0.010 |
Why?
| | Regression Analysis | 1 | 1997 | 1047 | 0.010 |
Why?
| | Institutionalization | 1 | 1992 | 13 | 0.010 |
Why?
| | Survival Rate | 1 | 1997 | 1799 | 0.010 |
Why?
| | Organizational Policy | 1 | 1991 | 75 | 0.010 |
Why?
| | Sex Factors | 1 | 1997 | 1901 | 0.010 |
Why?
|
|
Burton's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|